Metagenomi Therapeutics
MGX
69 hedge funds and large institutions have $870M invested in Metagenomi Therapeutics in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 20 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 20
5.57% less ownership
Funds ownership: 26.18% → 20.61% (-5.6%)
13% less funds holding
Funds holding: 79 → 69 (-10)
15% less capital invested
Capital invested by funds: $1.02B → $870M (-$148M)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$1.08M |
| 2 |
Millennium Management
New York
|
+$310K |
| 3 |
Jane Street
New York
|
+$249K |
| 4 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
+$244K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$235K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.95M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$683K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$511K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$312K |
MGX Hedge Fund Activity: Q2 2025 in Review
69 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q2 2025, worth a combined $870M — down 15% from $1.02B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of MGX and 16 opened new positions — a net loss of 10 holders — while 20 trimmed existing stakes and 20 added.
The largest buyer was Pura Vida Investments, adding an estimated $1.08M. The largest seller was BlackRock, cutting an estimated $1.95M.
- 69 institutional investors held Metagenomi Therapeutics (MGX) as of Q2 2025, down from 79 in Q1 2025.
- Funds reported $870M of Metagenomi Therapeutics stock for Q2 2025, down 15% quarter-over-quarter.
- 16 funds opened new Metagenomi Therapeutics positions in Q2 2025 and 26 closed out, a net change of -10 holders.
- The largest Metagenomi Therapeutics buyer in Q2 2025 was Pura Vida Investments, an estimated $1.08M added.
- The largest Metagenomi Therapeutics seller in Q2 2025 was BlackRock, an estimated $1.95M sold.
Based on aggregated 13F filings for Q2 2025.